---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-005917"
form_type: "8-K"
ticker: "ACRS"
cik: "0001557746"
company_name: "Aclaris Therapeutics, Inc."
filed_at: "2023-04-14T23:59:59+00:00"
generated_at: "2026-06-17T01:55:00.691681+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "low"
source: SEC EDGAR
---

# Aclaris updates corporate presentation; no specific financial or pipeline news disclosed

## Summary
- Company furnished an updated corporate overview presentation on April 14, 2023.
- Presentation titled 'Empowering Patients Through Kinome Innovation' emphasizes kinase-focused pipeline.
- No material new data on drug candidates, financials, or regulatory milestones in the disclosed exhibit.

## SEC filing metadata
- accession: 0001558370-23-005917
- form_type: 8-K
- ticker: ACRS
- cik: 0001557746
- company_name: Aclaris Therapeutics, Inc.
- filed_at: 2023-04-14T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: low
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1557746/000155837023005917/0001558370-23-005917-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1557746/000155837023005917/acrs-20230414x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-005917
- JSON: https://secwatch.observer/filing/0001558370-23-005917.json
- Plain text: https://secwatch.observer/filing/0001558370-23-005917.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.